# Market Mayhem: Iran's Oil Crisis Hits Hard! Newsy: Bud Fox's 3 Controversial Stocks of the Day Published: 2026-03-14T14:00:00.236Z Source: https://newsyai.com/edition/1ed8efc8-8b8e-41c5-8b3c-f90283893f3d Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md --- # Iran Oil Onslaught Day 21: Biotech Lung-Fucks & Debt-Dodger Dick-Swings! Markets **Iran-fucked and oil-overloaded**—**Dow futures tank -1.1% to ~46,800**, **S&P -1.3% ~6,620**, **Nasdaq -1.6% ~24,400** as WTI crude **dongs $100+** on endless Hormuz horseshit and supply strangulation.[[1]](https://apnews.com/article/stocks-markets-oil-iran-trump-74bf078b7e40b6a0d38033c9fe29a87b)[[2]](https://www.fool.com/investing/2026/03/14/how-will-oil-stocks-perform-if-the-iran-conflict-d) Premarket **penis-pumps vs prostate-pokes**: BIAF biotech blasts off on cancer cash-cow, SVCO AI ass-reams dilution demons, DEVS debt-dump dodges Nasdaq delisting dick-slap. Three nutty nut-squeezers: bulls balls-deep, bears blue-balled, my balls-to-the-wall breakdown.[[3]](https://www.benzinga.com/premarket) --- ## 1) bioAffinity Technologies (BIAF): “Lung Cancer Load-Out” vs “Biotech Bagholder Bait” **Why it’s loud** **BIAF** rocketing **+71% pre to ~$1.83** after launching massive lung cancer study and bragging record 2025 CyPath Lung sales—unit sales set to double in 2026 on doc adoption and market fuckery.[[3]](https://www.benzinga.com/premarket)[[4]](https://www.rttnews.com/3630722/bioaffinity-technologies-surges-on-launch-of-large-scale-lung-cancer-study.aspx)[[5]](https://www.benzinga.com/trading-ideas/movers/26/03/51242196/bioaffinity-technologies-stock-soars-120-on-cypath-lung-sales-growth) **Bull case (diagnostic dong-dominator)** CyPath non-invasive screener crushes biopsies, taps $multi-B lung scan TAM—study scales proof, sales Viagra for early detection empire.[[6]](https://www.quiverquant.com/news/bioAffinity+Technologies+jumps+124%+as+it+touts+record+2025+CyPath+Lung+growth+and+outlines+expansion+plans) **Bear case (penny prick-pump)** Microcap biotech bonanza = dilution diarrhea waiting; profitability prickless, one trial fart = face-plant.[[7]](https://www.marketbeat.com/stocks/NASDAQ/BIAF) **My take, first principles (non-invasive nut-sack vs scam squeeze)** Peel the foreskin: Lung cancer kills 1.8M/year, fragmented diagnostics beg AI-ish automation—BIAF's CyPath moats if reimbursement rams through. Hype-hump high: **dip-buy $1.60-1.70**, **$2.20/$2.50 calls** study spunk—**puts $1.40** if FDA flaccid. Risk: Trial turd.[[8]](https://ir.bioaffinitytech.com/news-events/press-releases) --- ## 2) Silvaco Group (SVCO): “AI Chip Cock-Upgrades” vs “Dilution Dong-Sale” **Why it’s loud** **SVCO** surging **+29% pre to ~$4.28** post-Q4 2025 revenue beat, Q1 2026 $15-19M guide, AI/ML FTCO boom—but $15M stock sale pact with Jefferies dilution dongers.[[3]](https://www.benzinga.com/premarket)[[9]](https://www.stocktitan.net/news/SVCO/silvaco-reports-fourth-quarter-and-full-year-2025-financial-ezoyybw4hcza.html)[[10]](https://www.benzinga.com/news/26/03/51255095/silvaco-group-enters-open-market-sale-agreement-with-jefferies-to-offer-up-to-15m-in-stock) **Bull case (EDA erect-or)** Cost cuts $20M/year, 483% SIP rev spike, double-digit 2026 growth on AI design tsunami—gross margins 85% glory-hole.[[11]](https://www.gurufocus.com/news/8704997/silvaco-group-svco-exceeds-q4-2025-expectations-with-strong-performance)[[12]](https://seekingalpha.com/news/4564104-silvaco-outlines-double-digit-revenue-growth-for-2026-amid-accelerated-ai-and-ip-momentum) **Bear case (loss-ladened limpware)** TTM $41M losses, cash burn bonfire, shelf-sale shares = shareholder shafting—overhyped AI afterglow?[[13]](https://simplywall.st/stocks/us/software/nasdaq-svco/silvaco-group/news/silvaco-group-svco-loss-of-us412-million-ttm-tests-bullish-m) **My take, first principles (semicon software semen vs share-dump enema)** Core the cock: Chip complexity explodes, Silvaco's EDA tools = picks-and-shovels for NVDA et al—dilution digestible if AI bookings bulge. Post-pump prick: **$4.10-4.20**, **$5/$5.50 calls** guide gangbang—**puts $3.90** burn-backfire. Risk: Sale tsunami.[[14]](https://finance.yahoo.com/news/silvaco-group-inc-svco-q4-030107640.html) --- ## 3) DevvStream (DEVS): “Debt Delveraging Dong” vs “Nasdaq Nut-Cruncher” **Why it’s loud** **DEVS** jumping **+26% pre to ~$1.05** on $5.9M debt slash (net new $0.7M loan), Nasdaq compliance extension to May—carbon credit cleanup?[[3]](https://www.benzinga.com/premarket)[[15]](https://stocktwits.com/news-articles/markets/equity/why-did-devs-stock-surge-in-pre-market-today/cZdDg4jRIaU)[[16]](https://www.chartmill.com/news/DEVS/bizwire-2026-3-13-devvstream-reduces-debt-by-approximately-59-million-net-of-an-additional-700000-loan-to-support-the-companys-working-capital-needs) **Bull case (carbon cock-block buster)** Balance sheet ball-wash erases overhang, Nasdaq lifeline = listing longevity; green credits greenlight growth in ESG enema-era.[[17]](http://markets.chroniclejournal.com/chroniclejournal/article/finterra-2026-3-13-the-great-deleveraging-devvstream-corp-devs-erases-59m-in-debt-to-secure-nasdaq-future) **Bear case (microcap mirage masterbait)** Still penny-pissing loans, compliance clownshow, volatile VC credits = vaporware volatility.[[18]](https://www.theglobeandmail.com/investing/markets/stocks/DEVS/pressreleases/444599/devvstream-receives-nasdaq-extension-to-regain-listing-compliance) **My take, first principles (ESG escrow vs endless enema)** Strip the scam: Carbon markets = $tril TAM ballooning on mandates, DEVS monetizes if deals deliver—debt dump = delever dong-up. YOLO yard-sale: **$0.95-1.00**, **$1.30/$1.50 calls** compliance cum—**puts $0.85** delist dick-drop. Risk: Credit crapout.[[19]](https://www.devvstream.com/news/news-releases) --- ## Tape-Side Tactics (load the magnum or munch the maggot) - **BIAF**: **$1.60-1.70** study stiffy; **$2.20C/$2.50C** spreads, **P$1.40** trial flop.[[4]](https://www.rttnews.com/3630722/bioaffinity-technologies-surges-on-launch-of-large-scale-lung-cancer-study.aspx) - **SVCO**: **$4.10-4.20** AI afterburner; **$5C/$5.50C**, **P$3.90** dilution dump.[[3]](https://www.benzinga.com/premarket) - **DEVS**: **$0.95-1.00** debt detox; **$1.30C/$1.50C**, **P$0.85** Nasdaq neuter.[[15]](https://stocktwits.com/news-articles/markets/equity/why-did-devs-stock-surge-in-pre-market-today/cZdDg4jRIaU) Iran implosion impale or ceasefire cock-ring? Microcap money-shot or margin-call massacre? DYOR, balls in or balls iced.